PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation

Nature Communications

Volumn 5, Issue , 2014, Pages

  Kolodziej, Stephan ^a   Kuvardina, Olga N ^a   Oellerich, Thomas ^b   Herglotz, Julia ^a,e   Backert, Ingo ^a,f   Kohrs, Nicole ^a   Buscató, Estel La ^b   Wittmann, Sandra K ^b   Salinas Riester, Gabriela ^c   Bonig, Halvard ^b   Karas, Michael ^b   Serve, Hubert ^b,d   Proschak, Ewgenij ^b,d   Lausen, Jörn ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; DNA BINDING PROTEIN; HISTONE; IMMUNOGLOBULIN G; LYMPHOID ENHANCER FACTOR 1; NUCLEOSOME ASSEMBLY PROTEIN 1; PEPTIDYLARGININE DEIMINASE IV; PROTEIN ARGININE DEIMINASE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR TAL1; UNCLASSIFIED DRUG; CCCTC-BINDING FACTOR; GLYCOPROTEIN GP 130; HYDROLASE; IL6ST PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PEPTIDYLARGININE DEIMINASE TYPE IV; PRMT6 PROTEIN, HUMAN; PROTEIN ARGININE METHYLTRANSFERASE; REPRESSOR PROTEIN; TAL1 PROTEIN, HUMAN;

AMINO ACID; DRUG; GENE EXPRESSION; HEMATOLOGY; METHYLATION; PEPTIDE; PROTEIN;

ARTICLE; CELL DIFFERENTIATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLONY FORMATION; CONTROLLED STUDY; ERYTHROLEUKEMIA CELL; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; HEMATOPOIESIS; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; INTRON; K562 CELL LINE; LYMPHOCYTE DIFFERENTIATION; NUCLEIC ACID TRANSPORT; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REPRESSOR GENE; TRANSCRIPTION INITIATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; METHYLATION; TUMOR CELL LINE;

ARGININE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CYTOKINE RECEPTOR GP130; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HISTONES; HUMANS; HYDROLASES; METHYLATION; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN-ARGININE N-METHYLTRANSFERASES; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS;

EID: 84901773291     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4995     Document Type: Article

References (69)

1. Shivdasani, R. A., Mayer, E. L. & Orkin, S. H. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature 373, 432-434 (1995).
2. Robb, L. et al. Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. Proc. Natl Acad. Sci. USA 92, 7075-7079 (1995).
3. Porcher, C., Liao, E. C., Fujiwara, Y., Zon, L. I. & Orkin, S. H. Specification of hematopoietic and vascular development by the bHLH transcription factor SCL without direct DNA binding. Development 126, 4603-4615 (1999).
4. Visvader, J. E., Fujiwara, Y. & Orkin, S. H. Unsuspected role for the T-cell leukemia protein SCL/tal-1 in vascular development. Genes Dev. 12, 473-479 (1998). (Pubitemid 28101010)
5. Courtial, N. et al. Tal1 regulates osteoclast differentiation through suppression of the master regulator of cell fusion DC-STAMP. FASEB J. 26, 523-532 (2011).
6. Dey, S., Curtis, D. J., Jane, S. M. & Brandt, S. J. The TAL1/SCL transcription factor regulates cell cycle progression and proliferation in differentiating murine bone marrow monocyte precursors. Mol. Cell. Biol. 30, 2181-2192 (2010).
7. Hall, M. A. et al. The critical regulator of embryonic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis, erythropoiesis, and lineage choice in CFU-S12. Proc. Natl Acad. Sci. USA 100, 992-997 (2003). (Pubitemid 36183943)
8. Hall, M. A. et al. Functional but abnormal adult erythropoiesis in the absence of the stem cell leukemia gene. Mol. Cell. Biol. 25, 6355-6362 (2005). (Pubitemid 41023213)
9. Elwood, N. J., Zogos, H., Pereira, D. S., Dick, J. E. & Begley, C. G. Enhanced megakaryocyte and erythroid development from normal human CD34(+) cells: consequence of enforced expression of SCL. Blood 91, 3756-3765 (1998). (Pubitemid 28225743)
10. Lausen, J. et al. Targets of the Tal1 transcription factor in erythrocytes: E2 ubiquitin conjugase regulation by Tal1. J. Biol. Chem. 285, 5338-5346 (2010).
11. Goardon, N. et al. ETO2 coordinates cellular proliferation and differentiation during erythropoiesis. EMBO J. 25, 357-366 (2006). (Pubitemid 43152856)
12. Lacombe, J. et al. Scl regulates the quiescence and the long-term competence of hematopoietic stem cells. Blood 115, 792-803 (2010).
13. Chen, Q. et al. The tal gene undergoes chromosome translocation in T cell leukemia and potentially encodes a helix-loop-helix protein. EMBO J. 9, 415-424 (1990).
14. Finger, L. R. et al. Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia and melanoma. Proc. Natl Acad. Sci. USA 86, 5039-5043 (1989). (Pubitemid 19182228)
15. Palomero, T. et al. Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia. Blood 108, 986-992 (2006). (Pubitemid 44154635)
16. Larson, R. C. et al. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J. 15, 1021-1027 (1996). (Pubitemid 26077830)
17. Draheim, K. M. et al. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice. Oncogene 30, 1252-1260 (2011).
18. Condorelli, G. L. et al. T-cell-directed TAL-1 expression induces T-cell malignancies in transgenic mice. Cancer Res. 56, 5113-5119 (1996). (Pubitemid 26383021)
19. Kelliher, M. A., Seldin, D. C. & Leder, P. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha. EMBO J. 15, 5160-5166 (1996). (Pubitemid 26336198)
20. Tijssen, M. R. et al. Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators. Dev. Cell 20, 597-609 (2011).
21. Wilson, N. K. et al. The transcriptional program controlled by the stem cell leukemia gene Scl/Tal1 during early embryonic hematopoietic development. Blood 113, 5456-5465 (2009).
22. Wadman, I. A. et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J. 16, 3145-3157 (1997). (Pubitemid 27234954)
23. Schuh, A. H. et al. ETO-2 associates with SCL in erythroid cells and megakaryocytes and provides repressor functions in erythropoiesis. Mol. Cell. Biol. 25, 10235-10250 (2005). (Pubitemid 41681951)
24. Palii, C. G. et al. Differential genomic targeting of the transcription factor TAL1 in alternate haematopoietic lineages. EMBO J. 30, 494-509 (2011).
25. Huang, S., Qiu, Y., Stein, R. W. & Brandt, S. J. p300 functions as a transcriptional coactivator for the TAL1/SCL oncoprotein. Oncogene 18, 4958-4967 (1999). (Pubitemid 29425302)
26. Huang, S. & Brandt, S. J. mSin3A regulates murine erythroleukemia cell differentiation through association with the TAL1 (or SCL) transcription factor. Mol. Cell. Biol. 20, 2248-2259 (2000). (Pubitemid 30123840)
27. Huang, S., Qiu, Y., Shi, Y., Xu, Z. & Brandt, S. J. P/CAF-mediated acetylation regulates the function of the basic helix-loop-helix transcription factor TAL1/SCL. EMBO J. 19, 6792-6803 (2000). (Pubitemid 32011672)
28. Hu, X. et al. LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis. Proc. Natl Acad. Sci. USA 106, 10141-10146 (2009).
29. Hagiwara, T., Nakashima, K., Hirano, H., Senshu, T. & Yamada, M. Deimination of arginine residues in nucleophosmin/B23 and histones in HL-60 granulocytes. Biochem. Biophys. Res. Commun. 290, 979-983 (2002). (Pubitemid 34687458)
30. Cuthbert, G. L. et al. Histone deimination antagonizes arginine methylation. Cell 118, 545-553 (2004). (Pubitemid 39179708)
31. Wang, Y. et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306, 279-283 (2004). (Pubitemid 39336873)
32. Denis, H. et al. Functional connection between deimination and deacetylation of histones. Mol. Cell. Biol. 29, 4982-4993 (2009).
33. Li, P. et al. Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol. Cell. Biol. 28, 4745-4758 (2008).
34. Yao, H. et al. Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J. Biol. Chem. 283, 20060-20068 (2008).
35. Li, P. et al. Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression. Oncogene 29, 3153-3162 (2010).
36. Sharma, P. et al. Citrullination of histone H3 interferes with HP1-mediated transcriptional repression. PLoS Genet. 8, e1002934 (2012).
37. Tanikawa, C. et al. Regulation of histone modification and chromatin structure by the p53-PADI4 pathway. Nat. Commun. 3, 676 (2012).
38. Zhang, X. et al. Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos expression in breast cancer cells. PLoS Genet. 7, e1002112 (2011).
39. Chang, X. & Han, J. Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol. Carcinog. 45, 183-196 (2006). (Pubitemid 43358151)
40. Nakashima, K. et al. PAD4 regulates proliferation of multipotent haematopoietic cells by controlling c-myc expression. Nat. Commun. 4, 1836 (2013).
41. Christophorou, M. A. et al. Citrullination regulates pluripotency and histone H1 binding to chromatin. Nature 507, 104-108 (2014).
42. Slack, J. L., Causey, C. P. & Thompson, P. R. Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell. Mol. Life Sci. 68, 709-720 (2011).
43. Vermeulen, M., Hubner, N. C. & Mann, M. High confidence determination of specific protein-protein interactions using quantitative mass spectrometry. Curr. Opin. Biotechnol. 19, 331-337 (2008).
44. de Boer, E. et al. Efficient biotinylation and single-step purification of tagged transcription factors in mammalian cells and transgenic mice. Proc. Natl Acad. Sci. USA 100, 7480-7485 (2003). (Pubitemid 36759995)
45. Torrano, V. et al. CTCF regulates growth and erythroid differentiation of human myeloid leukemia cells. J. Biol. Chem. 280, 28152-28161 (2005). (Pubitemid 41076934)
46. Tanimoto, K. et al. Human beta-globin locus control region HS5 contains CTCF- and developmental stage-dependent enhancer-blocking activity in erythroid cells. Mol. Cell. Biol. 23, 8946-8952 (2003). (Pubitemid 37499785)
47. Farrell, C. M., West, A. G. & Felsenfeld, G. Conserved CTCF insulator elements flank the mouse and human beta-globin loci. Mol. Cell. Biol. 22, 3820-3831 (2002). (Pubitemid 34525223)
48. Mahajan, M. C., Karmakar, S., Newburger, P. E., Krause, D. S. & Weissman, S. M. Dynamics of alpha-globin locus chromatin structure and gene expression during erythroid differentiation of human CD34(+) cells in culture. Exp. Hematol. 37, 1143-1156 e3 (2009).
49. Arita, K. et al. Structural basis for Ca(2+)-induced activation of human PAD4. Nat. Struct. Mol. Biol. 11, 777-783 (2004). (Pubitemid 39014504)
50. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
51. Audet, J., Miller, C. L., Rose-John, S., Piret, J. M. & Eaves, C. J. Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells. Proc. Natl Acad. Sci. USA 98, 1757-1762 (2001). (Pubitemid 32165571)
52. Jenkins, B. J., Roberts, A. W., Najdovska, M., Grail, D. & Ernst, M. The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis. Blood 105, 3512-3520 (2005). (Pubitemid 40628193)
53. Sui, X. et al. Soluble interleukin-6 (IL-6) receptor with IL-6 stimulates megakaryopoiesis from human CD34(+) cells through glycoprotein (gp)130 signaling. Blood 93, 2525-2532 (1999). (Pubitemid 29181184)
54. Jones, S. A., Scheller, J. & Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375-3383 (2011).
55. Hong, D. S., Angelo, L. S. & Kurzrock, R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 110, 1911-1928 (2007). (Pubitemid 350036849)
56. Luo, Y. et al. Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry 45, 11727-11736 (2006). (Pubitemid 44497800)
57. Bauer, U. M., Daujat, S., Nielsen, S. J., Nightingale, K. & Kouzarides, T. Methylation at arginine 17 of histone H3 is linked to gene activation. EMBO Rep. 3, 39-44 (2002). (Pubitemid 34144813)
58. Guccione, E. et al. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature 449, 933-937 (2007). (Pubitemid 47598605)
59. Hyllus, D. et al. PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation. Genes Dev. 21, 3369-3380 (2007). (Pubitemid 350277762)
60. Herglotz, J. et al. Histone arginine methylation keeps RUNX1 target genes in an intermediate state. Oncogene 32, 2565-2575 (2013).
61. Kirmizis, A. et al. Arginine methylation at histone H3R2 controls deposition of H3K4 trimethylation. Nature 449, 928-932 (2007). (Pubitemid 47598603)
62. Iberg, A. N. et al. Arginine methylation of the histone H3 tail impedes effector binding. J. Biol. Chem. 283, 3006-3010 (2008).
63. Schreiber, E., Matthias, P., Muller, M. M. & Schaffner, W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 17, 6419 (1989). (Pubitemid 19198635)
64. Lausen, J., Cho, S., Liu, S. & Werner, M. H. The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO. J. Biol. Chem. 279, 49281-49288 (2004). (Pubitemid 39625814)
65. Knuckley, B., Causey, C. P., Pellechia, P. J., Cook, P. F. & Thompson, P. R. Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation. Chembiochem 11, 161-165 (2010).
66. Opitz, L. et al. Impact of RNA degradation on gene expression profiling. BMC Med. Genomics 3, 36 (2010).
67. Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3 Article 3 (2004).
68. Gentleman, R. C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).
69. Arita, K. et al. Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4. Proc. Natl Acad. Sci. USA 103, 5291-5296 (2006).